Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DR 0201

Next Previous
Drug Profile

DR 0201

Alternative Names: DR-0201; SAR-448501

Latest Information Update: 06 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dren Bio
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Myeloid cell stimulants; Phagocyte stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders; Non-Hodgkin's lymphoma

Most Recent Events

  • 27 May 2025 Sanofi acquires DR 0201 from Dren Bio
  • 17 Dec 2024 Phase-I clinical trials in Autoimmune disorders in New Zealand (IV) (NCT06647069)
  • 21 Oct 2024 Dren Bio plans a phase I trial for Autoimmune disorder in Australia, Bosnia, Herzegovina, Bulgaria, New Zealand, South Africa in November 2024 (Parenteral) (NCT06647069)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top